Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Ligand (Nasdaq: LGND) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, and will host a conference call at 8:30 a.m. ET with live webcast and replay available.

Rhea-AI Summary

Ligand (Nasdaq: LGND) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, and will host a conference call at 8:30 a.m. ET with live webcast and replay available.

The company described its asset-light royalty and technology licensing model, highlighted Captisol and NITRICIL platforms, and urged investors to monitor its investor relations website and X for material disclosures.

Argus Feb 12 session

-2.32% close to close Open Argus

Details

News Market Reaction – LGND

On Feb 12, the day this news came out, LGND closed 2.32% below the previous close.

Data tracked by StockTitan Argus for the Feb 12 session.

Key Figures

Earnings release date: February 26, 2026 Conference call time: 8:30 AM ET Conference ID: 3661098 +2 more

Earnings release date

February 26, 2026

Q4 and full year 2025 financial results

Conference call time

8:30 AM ET

Q4 and full year 2025 earnings call

Conference ID

3661098

Dial-in identifier for earnings call

US/Canada dial-in

(800) 715-9871

Domestic access number for call

International dial-in

(646) 307-1963

International access number for call

Historical Context

5 past events · Latest: 2026-02-04

5 events

1. 2026-02-04

   Conference appearance

   24h Move

   -0.3%

   Management participation in Oppenheimer healthcare conference and investor meetings.

2. 2025-12-09

   Investor Day guidance

   24h Move

   +0.6%

   2026 revenue and EPS guidance plus long-term royalty growth outlook.

3. 2025-11-06

   Q3 2025 earnings

   24h Move

   +9.4%

   Strong Q3 results and raised 2025 revenue and EPS guidance.

4. 2025-10-30

   Investor conferences

   24h Move

   +2.3%

   Planned participation in multiple November 2025 investor conferences.

5. 2025-10-23

   Earnings date notice

   24h Move

   -0.2%

   Scheduling of Q3 2025 earnings release and conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

regulation fd, cyclodextrin

2 terms

regulation fd regulatory

"for complying with our disclosure obligations under Regulation FD."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

cyclodextrin medical

"Captisolae platform technology is a chemically modified cyclodextrin with a structure"

Cyclodextrin is a ring-shaped sugar molecule used in medications to trap and carry other substances, improving a drug’s solubility, stability and how well it is absorbed in the body. For investors, its use can affect a product’s effectiveness, manufacturing complexity, regulatory review and patent strategy—like adding a protective container that makes a fragile item easier to ship, which can alter development costs and market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update.

Conference Call and Webcast Information
Date:	Thursday, February 26, 2026
Time:	8:30 AM Eastern Time
Conference Call:	(800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID 3661098
Webcast:	Live and replay webcasts of the call are available here.

About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:         
Kellie Walsh
media@ligand.com
(914) 315-6072

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ligand (LGND) report Q4 and full-year 2025 results?

Ligand will report on Thursday, February 26, 2026 and hold a results call at 8:30 a.m. ET. According to the company, investors can listen via live webcast or replay and should monitor the investor relations website and X for disclosures and materials.

How can investors access Ligand (LGND) earnings call on February 26, 2026?

Investors can join the conference call by phone or via live webcast and replay. According to the company, U.S. callers use (800) 715-9871, international callers use (646) 307-1963, conference ID 3661098, and the webcast is available on the investor relations site.

What time is Ligand's (LGND) earnings call for 2025 results on Feb 26, 2026?

The earnings call begins at 8:30 a.m. Eastern Time on February 26, 2026. According to the company, the call will include financial results and a general business update, with a live webcast and replay accessible for investors.

What business model and platforms did Ligand (LGND) highlight in its Feb 12, 2026 announcement?

Ligand described an asset-light model focused on financing, licensing, and royalties to generate diversified product revenue streams. According to the company, key technologies include the Captisol solubility platform and the NITRICIL tunable dosing platform.

Will Ligand (LGND) publish materials or regulatory disclosures around the Feb 26, 2026 earnings release?

Yes. Ligand said it uses its investor relations website and X to disclose material non-public information and comply with Regulation FD. According to the company, investors should monitor those channels, press releases, SEC filings, and the earnings webcast for updates.